Research Analysts Set Expectations for ELDN FY2025 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Cantor Fitzgerald lifted their FY2025 EPS estimates for Eledon Pharmaceuticals in a research report issued on Thursday, May 15th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company will earn ($0.73) per share for the year, up from their previous estimate of ($1.23). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share.

Separately, Guggenheim initiated coverage on Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They issued a “buy” rating and a $9.00 target price for the company.

Eledon Pharmaceuticals Trading Down 0.7%

NASDAQ:ELDN opened at $2.87 on Monday. Eledon Pharmaceuticals has a 12 month low of $2.30 and a 12 month high of $5.54. The firm’s 50 day moving average is $3.17 and its 200 day moving average is $3.94. The stock has a market capitalization of $171.86 million, a PE ratio of -1.43 and a beta of 0.08.

Eledon Pharmaceuticals (NASDAQ:ELDN) last released its earnings results on Wednesday, May 14th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.20.

Institutional Investors Weigh In On Eledon Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ELDN. Tower Research Capital LLC TRC increased its stake in shares of Eledon Pharmaceuticals by 418.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock worth $33,000 after purchasing an additional 6,412 shares in the last quarter. CW Advisors LLC bought a new position in Eledon Pharmaceuticals in the 1st quarter worth approximately $34,000. Y Intercept Hong Kong Ltd bought a new position in Eledon Pharmaceuticals in the 1st quarter worth approximately $41,000. Alpine Global Management LLC purchased a new position in Eledon Pharmaceuticals in the 4th quarter valued at approximately $56,000. Finally, ADAR1 Capital Management LLC bought a new stake in Eledon Pharmaceuticals during the 4th quarter valued at $66,000. 56.77% of the stock is owned by hedge funds and other institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).